We are proud to announce that we have received more than €1M in venture capital funding from a group of Belgian investors and an additional €250 000 in research funds from the IWT, a government agency for Innovation by Science and Technology.
The investors include former MedHold CEO Annie Vereecken, Cartagenia CEO Herman Verrelst and a KULeuven investment group led by professor Bart De Moor.
LRM, a Belgian investment company, will also support UgenTec with a loan of €100,000.
Read the official press release.
Read the article in Genomeweb.